India’s TB patients can finally celebrate the end of Johnson & Johnson’s monopoly disguised as charity
Daybreak
00:00
The Indian Government's Decision to Refuse an Extension of Its Patent for Barakulin
Indian authorities are finally beginning to rethink the charity system. India has been rationing these drugs, carefully tailoring treatment guidelines according to availability. The decision by the patent office opens the doors for other companies to produce accessible versions with some health experts estimating that the cost of the treatment could be cut down by 80%. For the two women who have been fighting to bring down Johnson & Johnson's patent protection, it is a bittersweet story.
Play episode from 05:30
Transcript
